PLATINUM SPONSORS

Eli Lilly and Company is a global healthcare leader dedicated to discovering, developing, and delivering innovative medicines that make life better for people around the world. With a legacy spanning nearly 150 years, Lilly has been at the forefront of scientific breakthroughs in areas such as diabetes, oncology, immunology, and neuroscience. The company’s pioneering work in biologics, gene therapy, and next-generation therapeutics continues to drive advancements in patient care. Committed to fostering innovation, Lilly actively collaborates with researchers, biotech startups, and entrepreneurs to translate cutting-edge science into life-changing treatments. As a proud sponsor of Nucleate, Lilly supports the next generation of biotech leaders and aims to accelerate transformative breakthroughs in healthcare.

Genentech, a member of the Roche Group, is a pioneer in biotechnology, revolutionizing medicine through groundbreaking research in oncology, immunology, neuroscience, and rare diseases. With a relentless commitment to science-driven innovation, Genentech has developed life-saving therapies that have transformed the treatment of cancer, autoimmune disorders, and other complex diseases. The company’s deep expertise in biologics, precision medicine, and antibody engineering continues to shape the future of healthcare. Beyond scientific excellence, Genentech is dedicated to fostering the next generation of biotech entrepreneurs and innovators. As a proud sponsor of Nucleate, Genentech supports emerging leaders in life sciences, empowering them to bring bold ideas from bench to bedside.

Alnylam Pharmaceuticals is a global leader in RNA interference (RNAi) therapeutics, pioneering a new class of medicines that harness the body’s natural gene-silencing mechanisms to target and treat diseases at their genetic source. With a robust pipeline spanning rare and prevalent diseases, Alnylam has delivered multiple FDA-approved treatments for conditions such as hereditary transthyretin-mediated amyloidosis (hATTR), acute hepatic porphyria, and primary hyperoxaluria type 1. The company continues to expand its scientific platform, driving innovation in genetic medicine and partnering with researchers, biotech startups, and industry leaders to advance the next generation of RNAi-based therapies. As a proud sponsor of Nucleate, Alnylam is committed to fostering the next wave of biotech entrepreneurs and accelerating breakthroughs in life sciences.

MilliporeSigma, the U.S. and Canada life science business of Merck KGaA, Darmstadt, Germany, is a global leader in providing innovative tools, technologies, and services that drive scientific discovery and biomanufacturing. With a comprehensive portfolio spanning reagents, chemicals, lab equipment, and cutting-edge bioprocessing solutions, MilliporeSigma empowers researchers and biotech companies to accelerate breakthroughs in healthcare, synthetic biology, and beyond. The company is deeply committed to advancing science through collaboration, supporting startups, and fostering the next generation of innovators. As a proud sponsor of Nucleate, MilliporeSigma is dedicated to equipping emerging biotech entrepreneurs with the resources and expertise needed to transform pioneering research into real-world impact.

SILVER SPONSORS

VENTURE

BANKING + SPEND

OPERATIONAL ACCOUNTING

GRANT WRITING

IN-KIND

PHILANTHROPIC